Sterling Capital Management’s SAB Biotherapeutics SABS Stock Holding History

Sterling Capital Management’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.41K	Buy	+875	New	+$3.26K	﹤0.01%	2802

Other funds holding SABS

HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return

New York State Common Retirement Fund

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Sterling Capital Management's SABS Position: Q2 2026 in Review

Sterling Capital Management opened a new position in SAB Biotherapeutics (SABS) in Q2 2026: 875 shares worth $3.41K. The stake represents ﹤0.01% of the portfolio and ranks #2802 among its holdings.

11 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

Sterling Capital Management held 875 shares of SAB Biotherapeutics worth $3.41K as of Q2 2026.
SAB Biotherapeutics was a new Sterling Capital Management position in Q2 2026.
SAB Biotherapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2802 holding.
11 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.